Working... Menu

Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00883051
Recruitment Status : Completed
First Posted : April 17, 2009
Last Update Posted : January 4, 2018
CoLucid Pharmaceuticals
Information provided by (Responsible Party):
Eli Lilly and Company